These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26011487)

  • 41. [Notch signaling proteins and oncogenesis].
    Gu F; Ma YJ; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):629-32. PubMed ID: 18070456
    [No Abstract]   [Full Text] [Related]  

  • 42. Targeting Notch degradation system provides promise for breast cancer therapeutics.
    Liu J; Shen JX; Wen XF; Guo YX; Zhang GJ
    Crit Rev Oncol Hematol; 2016 Aug; 104():21-9. PubMed ID: 27263934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paeoniflorin inhibits proliferation and invasion of breast cancer cells through suppressing Notch-1 signaling pathway.
    Zhang Q; Yuan Y; Cui J; Xiao T; Jiang D
    Biomed Pharmacother; 2016 Mar; 78():197-203. PubMed ID: 26898442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Molecular classification of breast cancers].
    Chen XS; Chen SJ; Shen KW
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):641-3. PubMed ID: 19173901
    [No Abstract]   [Full Text] [Related]  

  • 45. Bringing androgens up a NOTCH in breast cancer.
    Tarulli GA; Butler LM; Tilley WD; Hickey TE
    Endocr Relat Cancer; 2014 Aug; 21(4):T183-202. PubMed ID: 25001242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms driving local breast cancer recurrence in a model of breast-conserving surgery.
    Smith MJ; Culhane AC; Killeen S; Kelly MA; Wang JH; Cotter TG; Redmond HP
    Ann Surg Oncol; 2008 Oct; 15(10):2954-64. PubMed ID: 18622646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breast cancer cells promote a notch-dependent mesenchymal phenotype in endothelial cells participating to a pro-tumoral niche.
    Ghiabi P; Jiang J; Pasquier J; Maleki M; Abu-Kaoud N; Halabi N; Guerrouahen BS; Rafii S; Rafii A
    J Transl Med; 2015 Jan; 13():27. PubMed ID: 25623554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic value of tumour-stroma ratio in triple-negative breast cancer.
    Moorman AM; Vink R; Heijmans HJ; van der Palen J; Kouwenhoven EA
    Eur J Surg Oncol; 2012 Apr; 38(4):307-13. PubMed ID: 22264965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age, molecular subtypes and local therapy decision-making.
    Kuijer A; King TA
    Breast; 2017 Aug; 34 Suppl 1():S70-S77. PubMed ID: 28666919
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Changing behavior of estrogen and progesterone receptors with metastasis or recurrence of breast cancer].
    Morimoto K; Koh M; Yamamoto A; Tamura K; Yamamoto K; Yamamoto K; Suehiro S
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):925-9. PubMed ID: 16835481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence.
    Criscitiello C; Bagnardi V; Viale G; Disalvatore D; Rotmensz N; Esposito A; Goldhirsch A; Curigliano G
    Anticancer Res; 2016 Jul; 36(7):3537-40. PubMed ID: 27354620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
    Cefaro GA; Genovesi D; Trignani M; DI Nicola M
    Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. IRF6 Is Involved in the Regulation of Cell Proliferation and Transformation in MCF10A Cells Downstream of Notch Signaling.
    Zengin T; Ekinci B; Kucukkose C; Yalcin-Ozuysal O
    PLoS One; 2015; 10(7):e0132757. PubMed ID: 26161746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Efforts in the individualization of the adjuvant systemic therapy in breast cancer--ASCO, 2004].
    Kahán Z
    Magy Onkol; 2004; 48(3):268-9. PubMed ID: 15810166
    [No Abstract]   [Full Text] [Related]  

  • 55. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
    Tang P; Wang J; Hicks DG; Wang X; Schiffhauer L; McMahon L; Yang Q; Shayne M; Huston A; Skinner KA; Griggs J; Lyman G
    Cancer Invest; 2010 Nov; 28(9):978-82. PubMed ID: 20690804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1095-101. PubMed ID: 20638197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.
    Bancovik J; Moreira DF; Carrasco D; Yao J; Porter D; Moura R; Camargo A; Fontes-Oliveira CC; Malpartida MG; Carambula S; Vannier E; Strauss BE; Wakamatsu A; Alves VA; Logullo AF; Soares FA; Polyak K; Belizário JE
    BMC Cancer; 2015 Feb; 15():70. PubMed ID: 25879571
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic targets of triple-negative breast cancer: a review.
    Jamdade VS; Sethi N; Mundhe NA; Kumar P; Lahkar M; Sinha N
    Br J Pharmacol; 2015 Sep; 172(17):4228-37. PubMed ID: 26040571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting HER2 in Advanced Breast Cancer.
    Zhu X; Joy AA
    Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Personalized--Not Omitted--Radiation Oncology for Breast Cancer.
    Fiorentino A; Mazzola R; Ricchetti F; Fersino S; Giaj Levra N; Alongi F
    J Clin Oncol; 2015 Dec; 33(36):4313-4. PubMed ID: 26527787
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.